A new probable increasing cause of esophageal ulceration: Alendronate

American Journal of Gastroenterology

Volumn 92, Issue 4, 1997, Pages 704-706

  Colina, Ramon E ^a   Smith, Milton ^a   Kikendall, James Walter ^a   Wong, Roy K H ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; DIGESTIVE TRACT ENDOSCOPY; ESOPHAGUS ULCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LOWER ESOPHAGUS SPHINCTER; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCER HEALING;

ADULT; ALENDRONATE; BIOPSY; ESOPHAGEAL DISEASES; ESOPHAGOGASTRIC JUNCTION; ESOPHAGOSCOPY; FEMALE; HUMANS; ULCER;

EID: 0030897848     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Santora A. Proceedings, 12th International Conference on Calcium Regulating Hormones. Melbourne, Australia, February 1995: 14-19.
2. Black DM, Reiss TF, Nevitt MC, et al. Design of fracture intervention trial. Osteoporos Int 1993;3(suppl):S29-39.
3. Maconi G, Bianchi Porro G. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889.
4. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
5. Juncosa L. Ulcus peptico yatrogeno del esophagus. Rev Esp Enferm Apar Dig 1970;30:457-60.
6. Knauer CM, McLaughling WT, Mark JBD. Esophageal fistula in patient with achalasia. Gastroenterology 1970;58:223-8.
7. Pemberton J. Oesophageal obstruction and ulceration caused by oral potassium therapy. Br Heart J 1970;32:267-8.
8. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
9. Chestnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and remodeling. Am J Med 1995;99:144-52.
10. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-90.
11. Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal women. J Clin Endocrinol Metab 1993;76:1399-406.